Adherex Technologies (NASDAQ:FENC) Stock Price Expected to Rise, HC Wainwright Analyst Says

Adherex Technologies (NASDAQ:FENC – Get Free Report) had its price objective increased by investment analysts at HC Wainwright from $16.00 to $17.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright‘s target price would indicate a potential upside of 26.39% from the stock’s current price. HC Wainwright also issued estimates for Adherex Technologies’ Q3 2027 earnings at $0.28 EPS and Q4 2027 earnings at $0.33 EPS.

A number of other equities analysts have also recently weighed in on the company. Weiss Ratings raised Adherex Technologies from a “sell (d-)” rating to a “hold (c-)” rating in a report on Friday, November 13th. B. Riley Financial restated a “buy” rating and issued a $19.00 price objective (up from $18.00) on shares of Adherex Technologies in a research report on Monday. Zacks Research raised Adherex Technologies from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 12th. Finally, Wedbush increased their target price on Adherex Technologies from $13.00 to $16.00 and gave the company an “outperform” rating in a research report on Wednesday, August 12th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, Adherex Technologies currently has an average rating of “Buy” and an average target price of $17.50.

Get Our Latest Research Report on Adherex Technologies

Adherex Technologies Stock Performance

FENC opened at $13.45 on Wednesday. Adherex Technologies has a fifty-two week low of $5.65 and a fifty-two week high of $13.85. The company has a fifty day moving average of $10.75 and a two-hundred day moving average of $9.47. The stock has a market capitalization of $473.71 million, a price-to-earnings ratio of 190.43 and a beta of 1.29.

Adherex Technologies (NASDAQ:FENC – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.10 by $0.02. Adherex Technologies had a net margin of 2.52% and a return on equity of 8.96%. The business had revenue of $19.61 million during the quarter, compared to the consensus estimate of $18.87 million. On average, equities research analysts forecast that Adherex Technologies will post 0.32 earnings per share for the current year.

Insider Activity at Adherex Technologies

In other Adherex Technologies news, insider Pierre Sargis Sayad sold 12,000 shares of the business’s stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $12.18, for a total transaction of $146,160.00. Following the completion of the sale, the insider directly owned 9,519 shares in the company, valued at approximately $115,941.42. The trade was a 55.76% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Robert Andrade sold 75,000 shares of the stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $11.78, for a total value of $883,500.00. Following the transaction, the chief financial officer directly owned 217,675 shares of the company’s stock, valued at $2,564,211.50. The trade was a 25.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.73% of the stock is currently owned by insiders.

Adherex Technologies Company Profile

(Get Free Report)

Adherex Technologies was a biotechnology company focused on developing treatments for cancer. In 2014, the company changed its name to Fennec Pharmaceuticals Inc.; Fennec later adopted the Nasdaq ticker FENC. Fennec is a commercial-stage biopharmaceutical company focused on therapies that address complications of cancer treatment. Its principal product is PEDMARK, a sodium thiosulfate injection approved in the United States to reduce the risk of cisplatin-related hearing damage in certain pediatric patients with cancer.

Recommended Stories

Analyst Recommendations for Adherex Technologies (NASDAQ:FENC)

Receive News & Ratings for Adherex Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adherex Technologies and related companies with MarketBeat.com's FREE daily email newsletter.